The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).
 
Ethan M. Basch
No Relationships to Disclose
 
Mark C. Scholz
Honoraria - Janssen; Medivation
Consulting or Advisory Role - Janssen; Medivation
Speakers' Bureau - Janssen; Medivation
Research Funding - Exelixis (Inst)
Travel, Accommodations, Expenses - Janssen; Medivation
 
Johann Sebastian De Bono
Honoraria - Astellas Pharma; AstraZeneca; Genentech/Roche; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Genentech/Roche; Sanofi
Research Funding - Arno Therapeutics (Inst); AstraZeneca (Inst); Genentech (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Abbvie; Bavarian Nordic; Dava Oncology; Endocyte; Mannkind; UpToDate
Consulting or Advisory Role - Amgen; AVEO; BIND Biosciences; Janssen Biotech
Speakers' Bureau - Bayer; Caris MPI; Dendreon; GlaxoSmithKline; Medivation; Millennium; Sanofi
Research Funding - Endocyte (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Parexel (Inst); Progenics (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bayer/Onyx; Celgene; Dendreon; Exelixis; Genentech/Roche; Novartis; Pfizer; US Oncology
 
Paul L. De Souza
Honoraria - Janssen
Research Funding - Exelixis (Inst)
Expert Testimony - Janssen
 
Gavin M. Marx
Honoraria - Amgen; Janssen; Roche; Sanofi
Consulting or Advisory Role - Amgen; Janssen; Sanofi
Research Funding - Exelixis (Inst)
Travel, Accommodations, Expenses - Sanofi
 
Ulka N. Vaishampayan
Honoraria - Astellas Pharma; Bayer; Janssen; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Novartis; Pfizer
Speakers' Bureau - Astellas Pharma; Bayer; Janssen; Novartis; Pfizer
Research Funding - Astellas Pharma; Exelixis; Novartis
 
Saby George
Employment - Amgen (I)
Consulting or Advisory Role - Astellas Pharma; Bayer; Novartis; Sanofi
Research Funding - Exelixis (Inst); GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Sanofi
 
James K. Schwarz
Research Funding - Exelixis (Inst)
 
Emmanuel S. Antonarakis
Honoraria - Dendreon; Janssen Biotech; Medivation; Sanofi
Consulting or Advisory Role - Dendreon; Janssen Biotech; Medivation; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi
 
Joe M. O'Sullivan
Honoraria - Astellas Pharma; Bayer; Janssen
Consulting or Advisory Role - Bayer
Speakers' Bureau - Bayer; Janssen
Research Funding - Bayer; Exelixis (Inst)
 
Arash Rezazadeh Kalebasty
Honoraria - Amgen; Astellas Pharma; Dendreon; Janssen
Consulting or Advisory Role - Janssen
Speakers' Bureau - Amgen; Astellas Pharma; Dendreon; Janssen
Research Funding - Exelixis (Inst); Genentech
 
Kim N. Chi
Honoraria - Astellas Pharma; Janssen; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; ESSA; Janssen; Lilly/ImClone; Sanofi; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Exelixis (Inst); Janssen (Inst); Novartis (Inst); Oncogenex (Inst); Sanofi (Inst); Teva (Inst); Tokai Pharmaceuticals (Inst)
 
Robert Dreicer
Honoraria - Bayer
Consulting or Advisory Role - Dendreon; Endo Pharmaceuticals; Janssen Oncology; Medivation; Millennium; Roche
Research Funding - Millennium (Inst)
 
Thomas E. Hutson
Employment - Texas Oncology
Honoraria - Bayer/Onyx; Dendreon; GlaxoSmithKline; Johnson & Johnson; Medivation; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bayer/Onyx; GlaxoSmithKline; GlaxoSmithKline; Novartis; Pfizer
Speakers' Bureau - Bayer/Onyx; Dendreon; GlaxoSmithKline; Johnson & Johnson; Medivation; Pfizer
Research Funding - GlaxoSmithKline (Inst); Johnson & Johnson (Inst); Medivation (Inst); Pfizer (Inst)
 
Milan Mangeshkar
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
Research Funding - Exelixis (Inst)
 
Jaymes S. Holland
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
Patents, Royalties, Other Intellectual Property - Exelixis
 
Aaron Weitzman
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
Research Funding - Exelixis
 
Howard I. Scher
Honoraria - Chugai Pharma
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Celgene; Endo Pharmaceuticals; Endocyte; Exelixis; Ferring; Foundation Medicine; Genentech; Janssen; Medivation; OncologySTAT; Palmetto GBA; Pfizer; Sanofi; Takeda; Ventana Medical Systems; WIRB-Copernicus Group
Speakers' Bureau - WebMD
Research Funding - BIND Biosciences (Inst); Epic Sciences (Inst); Exelixis (Inst); Guardant Health (Inst); Janssen (Inst); Janssen Diagnostics (Inst); Medivation (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Celgene; Endocyte; Exelixis; Ferring; Genentech; Janssen; Pfizer; Sanofi; Takeda; WIRB-Copernicus Group